BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China

详细信息    查看全文

• 作者：Xiangqian Zheng (1)
  Tingting Xia (1)
  Lin Lin (1)
  Songyuan Gao (2)
  Yigong Lee (1)
  Yang Yu (1)
  Songfeng Wei (1)
  Ming Gao (1) (3)
  
• 关键词：Papillary thyroid carcinoma ; Multiple PTC ; Solitary PTC ; BRAFV600E mutation
• 刊名：World Journal of Surgical Oncology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：10
• 期：1
• 全文大小：202KB
• 参考文献：1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-995. / Cancer 1998, 83:2638-648. CrossRef
  2. Schlumberger MJ: Papillary and follicular thyroid carcinoma. / N Eng J Med 1998, 338:297-06. CrossRef
  3. Davies L, Welch HG: Thyroid cancer survival in the United States: observational data from 1973 to 2005. / Arch Otolaryngol Head Neck Surg 2010,136(5):440-44. CrossRef
  4. Leenhardt L, Bernier MO, Boin-Pineau MH: Advances in diagnostic practices affect thyroid cancer incidence in France. / Eur J Endocrinol 2004,150(2):133-39. CrossRef
  5. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J: Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. / Cancer 1985, 55:805-28. CrossRef
  6. Russell WO, Ibanez ML, Clark RL, White EC: Thyroid carcinoma classification, intraglandular dissemination, and clinicopathological study based upon whole organ section of 80 glands. / Cancer 1963, 16:1425-460. CrossRef
  7. Udelsman R, Chen H: The current management of thyroid cancer. / Adv Surg 1999, 33:1-7.
  8. DeLellis RA: Pathology and genetics of thyroid carcinoma. / J Surg Oncol 2006, 94:662-69. CrossRef
  9. Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A: Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. / Cancer 1992, 70:1585-590. CrossRef
  10. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. / Am J Med 1994, 97:418-28. CrossRef
  11. De Matos PS, Ferreira AP, Ward LS: Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgic series. / Endocr Pathol 2006, 17:165-73. CrossRef
  12. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL: Distinct multiple RET/PTC gene rearrangements in multiple papillary thyroid neoplasia. / J Clin Endocrinol Metab 1998, 83:4116-122. CrossRef
  13. Moniz S, Catarino AL, Marques AR, Cavaco B, Sobrinho L, Leite V: Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. / Eur J Endocrinol 2002, 146:27-3. CrossRef
  14. Shattuck TM, Westra WH, Ladenson PW, Arnold A: Independent clonal origins of distinct tumor foci in multiple papillary thyroid carcinoma. / N Engl J Med 2005, 352:2406-412. CrossRef
  15. Roti E, Degli Uberti EC, Bondanelli M, Braverman LE: Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. / Eur J Endocrinol 2008, 159:659-73. CrossRef
  16. Pazaitou-Panayiotou K, Capezzone M, Pacini F: Clinical features and therapeutic implication of papillary thyroid microcarcinoma. / Thyroid 2007, 17:1085-092. CrossRef
  17. Hay ID, Grant CS, Van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ: Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. / Surgery 1992, 112:1139-146. discussion 1146-137
  18. Baudin E, Travagli JP, Ropers J, / et al.: Microcarcinoma of the thyroid gland: the Gustave–Roussy Institute experience. / Cancer 1998, 83:553-59. CrossRef
  19. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH: Papillary microcarcinoma of the thyroid prognostic significance of lymph node metastasis and multiple. / Cancer 2003, 98:31-0. CrossRef
  20. ItoK SuginoK, OzakiO MimuraT, IwasakiH ItoK: Papillary microcarcinoma of the thyroid. / J Endocrinol Invest 1998, 21:445-48.
  21. Aherne Sinéad T, Smyth Paul C, Flavin Richard J: Geographical mapping of a multiple thyroid tumour using genetic alteration analysis & miRNA profiling. / Mol Cancer 2008, 7:89. CrossRef
  22. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, / et al.: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid carcinoma. / J Clin Endocrinol Metab 2003, 88:4393-397. CrossRef
  23. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, / et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. / J Clin Endocrinol Metab 2003, 88:5399-404. CrossRef
  24. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. / Cancer Res 2003, 63:4561-567.
  25. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. / Yonsei Med J 2004, 45:818-21.
  26. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, / et al.: BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. / J Clin Endocrinol Metab 2004, 89:2414-420. CrossRef
  27. Mazeh H, Samet Y, Hochstein D, Mizrahi I, Ariel I, Eid A, Freund HR: Multiple in well-differentiated thyroid carcinomas calls for total thyroidectomy. / Am J Surg 2010, 9:22.
  28. Vriens MR, Suh I, Moses W, / et al.: Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. / Thyroid 2009, 19:1343-349. CrossRef
  29. Huang BY, Lin JD, Chao TC: Therapeutic outcomes of papillary thyroid cancer patients in different risk groups. / Oncology 2011,80(1-):123-29. CrossRef
  30. Bozec A, Dassonville O, Chamorey E: Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. / Eur Arch Otorhinolaryngol 2011,268(8):1205-212. CrossRef
  31. Iida F, Yonekura M, Miyakawa M: Study of intraglandular dissemination of thyroid cancer. / Cancer 1969, 24:764-71. CrossRef
  32. Xiaoqi Lin, Finkelstein Sydney D, Bing Zhu, Silverman Jan F: Molecular analysis of multiple papillary thyroid carcinoma. / J Mol Endocrinol 2008, 41:195-03. CrossRef
  33. Xing M, / et al.: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. / Endocr Rev 2007, 28:742-62. CrossRef
  34. Frasca F, / et al.: BRAF(V600E) mutation and the biology of papillary thyroid cancer. / Endocr Relat Cancer 2008, 15:191-05. CrossRef
  35. Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. / Cancer 2007, 110:38-6. CrossRef
  36. Nucera C, Goldfarb M, Hodin R, / et al.: Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E). / Biochim Biophys Acta 2009,1795(2):152-61.
  37. Kim TY, Kim WB, Rhee YS, / et al.: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. / Clin Endocrinol (Oxf) 2006, 65:364-68. CrossRef
  38. Howell Gina M, Carty Sally E, Armstrong Michaele J: Both BRAF V600E mutation and older age (>65 Years)are associated with recurrent papillary thyroid cancer. / Ann Surg Oncol 2011, 5:19.
  39. Trovisco V, de Vieira Castro I, Soares P, Ma’ximo V, Silva P, Magalhaes J, / et al.: BRAF mutations are associated with histologic types of papillary thyroid carcinoma. / J Pathol 2004, 202:247-51. CrossRef
  40. Trovisco V, Soares P, Preto A, de Vieira Castro I, Lima J, Castro P, / et al.: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients-age but not with tumour aggressiveness. / Virchows Arch 2005, 446:589-95. CrossRef
  
• 作者单位：Xiangqian Zheng (1)
  Tingting Xia (1)
  Lin Lin (1)
  Songyuan Gao (2)
  Yigong Lee (1)
  Yang Yu (1)
  Songfeng Wei (1)
  Ming Gao (1) (3)
  
  1. Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China
  2. Department of Pathology, Tsinghua University Medical College, Tsinghua University, Beijing, P.R.China
  3. Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Hospital and Institute, Huanhuxi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, P.R. China
  

文摘

Background Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignancies. In most cases, it often presents as multifocal tumor. It has been reported that multifocal tumors are associated with elevated risk of lymph node and distant metastases. Multifocality is also one of the factors predicting prognosis. Recent studies show that BRAFV600E mutation occurs more frequently in aggressive PTC. The purpose of this study was to evaluate BRAFV600E status and clinicopathological features in multiple and solitary PTC. Methods We performed a retrospective study to analyze 512 PTC cases who received surgery, including 376 solitary PTCs and 136 multiple PTCs. Results Multiple PTC is more related to lymph node metastasis and vascular invasion than solitary PTC. However, the distant metastasis rate and 10-year survival rate showed no difference between these two groups. BRAFV600E mutation status was more frequent in multiple PTC patients with lymph node metastasis and late stage at diagnosis. Conclusion BRAFV600E mutation is most commonly associated with extra-thyroidal extension and lymph node metastasis in PTC. Multiple PTC patients with young age, large tumors and BRAFV600E mutation should be followed carefully. Our study provides useful information for PTC patients-followup and treatment.